艾塞那肽联合多烯磷脂酰胆碱治疗酒精性肝炎患者初步疗效研究*

doi:10.3969/j.issn.1672-5069.2025.05.019

Abstract

Abstract: Objective The aim of this study was to investigate therapeutic efficacy of exenatideplus oralpolyenephosphatidylcholine in the treatment of patients with alcoholic hepatitis (AH). Method A total of 102 patients with AH were recruited in our hospital between January 2022 and January 2024,and were randomly assigned to receive oral polyene phosphatidylcholine in 50 patients in control, or receive subcutaneous exenatide injection plus oral polyene phosphatidylcholine in 52 patients in combination group for three months. Serum hyaluronic acid (HA), type III procollagen (PC-Ⅲ), collagen fiber Ⅳ (ⅳ-C) and laminin (LN)) levels were detected by radioimmunoassay, and serum tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and IL-8 levels were assayed by ELISA. Result By end of three month treatment, serum ALT, AST,GGT and total bilirubin levels in combination groupwere(48.9±15.2)U/L, (45.6±12.5)U/L, (119.5±30.6)U/L and (23.1±5.6)μmol/L, all significantly lower than [(69.3±20.1)U/L,(79.6±18.1)U/L, (168.8±50.7)U/Land (33.5±6.9)μmol/L,respectively, P<0.05] in the control; serum HA, PC-Ⅲ,Ⅳ-C and LN levels in the combination group were (128.5±20.3)μg/L, (132.3±29.1)μg/L, (41.2±9.1)mg/mL and (105.4±20.6)mg/mL, all significantly lower than [(152.2±22.1)μg/L, (186.5±30.4)μg/L, (57.3±10.2)mg/mL and (134.5±20.1)mg/mL, respectively, P<0.05] in the control group; serum TNF-α,IL-6 and IL-8 levels in the combination group were (236.1±100.8)pg/L, (35.1±10.8)pg/L and (10.5±3.8)ng/L, all much lower than [(286.7±105.6)pg/L, (50.1±11.4)pg/L and (17.1±4.5)ng/L, respectively, P<0.05] in the control group; there was no significant difference in the incidence of adverse reactions between the two groups (13.5% vs. 10.0%, P>0.05). Conclusion Additional injection of exenatideat basis of oral polyenephosphatidylcholine therapy could improve liver function normal in patients with alcoholic hepatitis, which might be related to inhibition of body inflammatory reactions.

Key words: Alcoholic hepatitis, Exenatide, Polyenephosphatidylcholine, Therapy

Wang Xia, DuanWangwang, Li Menghui. Application of exenatide at base of oral polyenephosphatidylcholine in treatment of patients with alcoholic hepatitis[J]. Journal of Practical Hepatology, 2025, 28(5): 715-718.

References

[1] 刘露露,佟静,王炳元.酒精性肝炎临床治疗进展.中华肝脏病杂志, 2022,30(6):672-675.
[2] Yang L ,Ting T F ,Jin X Z ,et al.Polyenephosphatidylcholine ameliorates high fat diet-induced non-alcoholic fatty liver disease via remodeling metabolism and inflammation.Front Physiol,2022,28(13):810143-810143.
[3] 甘露,林倍思,苏燕娜,等. 胰高糖素样肽-1对非酒精性脂肪肝病状态下生长分化因子15表达的影响. 中华糖尿病杂志,2021,13(5):482-489.
[4] Peng C X ,Yan P ,Li Y Q .Responsive oligochitosannano-vesicles with ursodeoxycholic acidand exenatide for NAFLD synergistic therapy via SIRT1.Carbohydr polym,2022,288(15):119388-119388.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.酒精性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2): 170-176.
[6] Saleh, M B,LouvetA ,Ntandja W L C,et al.Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis.J Hepatol ,2021,75(4):912-923.
[7] 程艳洁,王鹏飞,李峻.水飞蓟素联合复方蛋氨酸胆碱治疗酒精性肝炎患者疗效及其对血清肝纤维化指标的影响.实用肝脏病杂志,2024,27(3):349-352.
[8] Yan DX ,Zi L W ,Guang J S ,et al.GSDMD induces hepatocyte pyroptosis to trigger alcoholic hepatitis through modulating mitochondrial dysfunction.Cell Div,2024,19(1):10-11.
[9] Gastaldelli A , Repetto E , Guja C ,et al.Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.DiabetesObesMetab , 2020, 22(3):393-403.
[10] Lule KO , Akarsu E , Sayiner ZA ,et al.The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.Inflammopharmacology, 2022, 30(1):243-250.
[11] Ying L ,Anni C ,Zhi ZL ,et al.Effectiveness of polyenephosphatidylcholine and its combination with other drugs in patients with liver diseases based on real-world research.Expert Rev ClinPharmacol ,2022,15(11):1363-1375.
[12] Ting TF , Xiao YY , Shan SH ,et al.TLR-2-mediated metabolic reprogramming participates in polyenephosphatidylcholine-mediated inhibition of M1 macrophage polarization.ImmunolRes, 2020, 68(1):28-38.
[13] Olga L ,Muhammad AG ,Mariam A,et al.Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT) .Diabetes Obes Metab,2022,24(5):899-907.
[14] Wojcicka G, Pradiuch A, FornalE,et al. The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome. BiochemPharmacol, 2023 ,214:115637.
[15] QimingY ,Xiang S ,Peng Y ,et al.Incorporation of glycyrrhizic acid and polyenephosphatidylcholine in lipid nanoparticles ameliorates acute liver injury via delivering p65 siRNA.Nanomedicine,2023,48(12):102649-102649.
[16] BurakM ,Adnan B .Effect of exenatide on nonalcoholic steatohepatitis and inflammation-related indices in diabetic patients with non-alcoholic fatty liver disease .MetabSyndrRelat Disord,2023,21(4):205-213.
[17] Ghadieh HE, Muturi HT, Najjar SM. Exenatide prevents diet-induced hepatocellular injury in A CEACAM1-dependent Mechanism. J Diabetes Treat, 2017,2017(4):10.
[18] Liu L, Yan H, Xia M, et al. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev, 2020,36(5):e3292.
[19] Ma, Z,Qian, P,Shen, R, et al.Pharmacologicalsignatures of the exenatidenanoparticles against hepatic ischemia/reperfusion-induced pancreatic injury.TransplantProc,2019,51(3):960-965.
[20] Saad ZA, Khodeer DM, ZaitoneSA,et al. Exenatide ameliorates experimental non-alcoholicfatty liver in rats via suppression of Toll-like receptor 4/NFκB signaling: Comparison to metformin. Life Sci,2020,15;(253):117725.

Application of exenatide at base of oral polyenephosphatidylcholine in treatment of patients with alcoholic hepatitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Cong Dongwei, Liu Lina, Gao Wenjuan, et al. Antiviral efficacy of pegylated interferon α-2b and entecavir or tenofovir in the treatment of patients with serum HBeAg-positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2025, 28(5): 655-658.
[2]	Chen Wenzhe, Wang Qingyuan, Chen Tian, et al. Impact of apolipoprotein B gene polymorphisms on response to pegylated interferon alpha-2b treatment in patients with serum HBeAg-positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2025, 28(5): 659-662.
[3]	Yuan Ling, Jiang Xia, Sun Meijie. Clinical efficacy of tenofovir amibufenamide and tenofovir alafenamide fumarate in rescue treatment of ETV-treated patients with chronic hepatitis B and low-level viremia [J]. Journal of Practical Hepatology, 2025, 28(5): 667-670.
[4]	Tang Qin, Hua Zhong, Su Qilin, et al. A preliminary study on efficacy of tenofovir amibufenamide and Biejiajian pill combination in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2025, 28(5): 671-674.
[5]	Hao Shuai, Wang Ziyi, Zhang Xinyi, et al. Normalized follow-up for hepatitis C micro-elimination strategy in a general tertiary hospital [J]. Journal of Practical Hepatology, 2025, 28(5): 675-678.
[6]	Liu Zhidong, Li Wensong, Gao Zhen, et al. Efficacy of daclatasvir and asunaprevir in the treatment of patients with naïve genotype 1b-infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2025, 28(5): 679-682.
[7]	Xin Wenyuan, Li Yuwei, Wu Jun. Efficacy of dalatavir combination with asulivir in the treatment of patients with chronic hepatitis C with genotype 1b infection [J]. Journal of Practical Hepatology, 2025, 28(5): 683-686.
[8]	Zhang Lei, Wang Yaru, Li Huiping, et al. Clinical observation of semaglutide and metformin combination in treatment of patients with type 2 diabetes mellitus and concomitant nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2025, 28(5): 699-702.
[9]	Liu Lihua, You Xiaohong, Fan Zhouhong. Combination of polyene phosphatidylcholine and silybin in treatment of patients with drug-induced liver injury: An analysis of 102 cases [J]. Journal of Practical Hepatology, 2025, 28(5): 723-726.
[10]	Zhu Yingjing, Wu Jie, Tian Xinyue, et al. Endoscopic tissue glue injection and esophageal variceal ligation in treatment of patients with hepatitis B-induced liver cirrhosis and esophageal and gastric varices bleeding [J]. Journal of Practical Hepatology, 2025, 28(5): 731-734.
[11]	Chen Jie, Yang Caimin, Peng Cailing, et al. Evaluation of histological changes based on Beijing standard in patients with hepatitis B-induced liver cirrhosis during entecavir antiviral therapy [J]. Journal of Practical Hepatology, 2025, 28(5): 735-738.
[12]	Mu Ya, Ge Naijian, Liu Xue, et al. Clinical efficacy of bevacizumab and sintilimab combination after TACE in the treatment of patients with unresectable hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2025, 28(5): 751-754.
[13]	Zhang Xiaozhao, Lei Kai, Qi Yabin, et al. Attilizumab and targeting and immune checkpoint inhibitor combination after TACE in the treatment of patients with advanced primary liver cancer [J]. Journal of Practical Hepatology, 2025, 28(5): 759-762.
[14]	Xu Jia, Peng Weiwei, Yin Na, et al. Clinical observation of sintilimab and anti-vascular endothelial growth factor antibody in the treatment of patients with unresectable hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2025, 28(5): 763-766.
[15]	Wang Jiahui, Cui Liming. TACE in combination with lenvatinib and sintilimab in the treatment of patients with beyondup-to-seven criteria hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2025, 28(5): 771-775.